AR078638A1 - Antagonistas del receptor de cgrp - Google Patents

Antagonistas del receptor de cgrp

Info

Publication number
AR078638A1
AR078638A1 ARP100103755A ARP100103755A AR078638A1 AR 078638 A1 AR078638 A1 AR 078638A1 AR P100103755 A ARP100103755 A AR P100103755A AR P100103755 A ARP100103755 A AR P100103755A AR 078638 A1 AR078638 A1 AR 078638A1
Authority
AR
Argentina
Prior art keywords
alkoxy
hydrogen
haloalkoxy
dialkylamino
azido
Prior art date
Application number
ARP100103755A
Other languages
English (en)
Inventor
Guanglin Luo
Gene M Dubowchik
John E Macor
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43242489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078638(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR078638A1 publication Critical patent/AR078638A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composiciones farmacéuticas y procedimientos para usar los compuestos en el tratamiento de trastornos relacionados con CGRP, incluidas migranas y otras cefaleas, vasodilatacion neurogénica, inflamacion neurogénica, lesion térmica, shock térmico, sofocos asociados con la menopausia, enfermedades inflamatorias de las vías aéreas tales como asma, y enfermedad pulmonar obstructiva cronica (EPOC). Reivindicacion 1: Un compuesto caracterizado porque tiene la formula 1: en la que: R1 es hidrogeno, ciano, halo, alquilo, haloalquilo, alcoxi, amino, alquilamino, dialquilamino, azetidinilo, pirrolidinilo o piperidinilo; R2 es piperidinilo sustituido con 1 sustituyente seleccionado del grupo de formulas 2 o R2 es el grupo de formulas 3; R3 es hidrogeno, halo, ciano, alquilo, haloalquilo, alcoxi o haloalcoxi; R4 es hidrogeno, halo, ciano, alquilo, haloalquilo, alcoxi o haloalcoxi; R5 es hidrogeno, hidroxi, alcoxi, haloalcoxi, azido, amino alquilamino o dialquilamino; R6 es hidrogeno, hidroxi, alcoxi, haloalcoxi, azido, amino alquilamino o dialquilamino; R7 es hidrogeno, hidroxi, alcoxi, haloalcoxi, azido, amino alquilamino o dialquilamino; R8 es hidrogeno, hidroxi, alcoxi, haloalcoxi, azido, amino alquilamino o dialquilamino; R9 es hidrogeno, hidroxi, alcoxi, haloalcoxi, azido, amino alquilamino o dialquilamino; R10 es hidrogeno, hidroxi, alcoxi, haloalcoxi, azido, amino alquilamino o dialquilamino; R11 es hidrogeno, hidroxi, alcoxi, haloalcoxi, azido, amino alquilamino o dialquilamino, alcoxicarbonilo o benciloxicarbonilo; o R10 y R11 juntos son OrN-OH; con la condicion de que al menos uno de R5, R6, R7, R8, R9, R10 o R11 no sea hidrogeno; Ar1 es fenilo sustituido con 0-3 sustituyentes seleccionados del grupo constituido por ciano, halo, alquilo, haloalquilo, alcoxi, haloalcoxi y alquilSO2 X es O, CH2 o NH; y Y es un enlace, O, CH2 o NH; o una sal farmacéuticamente aceptable del mismo.
ARP100103755A 2009-10-14 2010-10-14 Antagonistas del receptor de cgrp AR078638A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25147709P 2009-10-14 2009-10-14

Publications (1)

Publication Number Publication Date
AR078638A1 true AR078638A1 (es) 2011-11-23

Family

ID=43242489

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100103755A AR078638A1 (es) 2009-10-14 2010-10-14 Antagonistas del receptor de cgrp
ARP170103159A AR110069A2 (es) 2009-10-14 2017-11-13 Composiciones antagonistas del receptor de cgrp

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170103159A AR110069A2 (es) 2009-10-14 2017-11-13 Composiciones antagonistas del receptor de cgrp

Country Status (35)

Country Link
US (2) US8314117B2 (es)
EP (1) EP2488512B1 (es)
JP (3) JP5836279B2 (es)
KR (3) KR101755742B1 (es)
CN (1) CN102656159B (es)
AR (2) AR078638A1 (es)
AU (1) AU2010306954B2 (es)
BR (1) BR112012008828B1 (es)
CA (2) CA2777518C (es)
CL (1) CL2012000925A1 (es)
CO (1) CO6460732A2 (es)
CY (1) CY2022023I1 (es)
DK (1) DK2488512T3 (es)
EA (1) EA020409B1 (es)
ES (1) ES2441192T3 (es)
FR (1) FR22C1044I2 (es)
HK (1) HK1169390A1 (es)
HR (1) HRP20140111T1 (es)
HU (1) HUS2200033I1 (es)
IL (1) IL219120A (es)
LT (1) LTPA2022516I1 (es)
MX (1) MX2012004182A (es)
NL (1) NL301187I2 (es)
NO (1) NO2022033I1 (es)
NZ (1) NZ599281A (es)
PE (1) PE20121137A1 (es)
PL (1) PL2488512T3 (es)
PT (1) PT2488512E (es)
RS (1) RS53149B (es)
SI (1) SI2488512T1 (es)
SM (1) SMT201400019B (es)
TN (1) TN2012000139A1 (es)
TW (1) TWI465448B (es)
WO (1) WO2011046997A1 (es)
ZA (1) ZA201203452B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) * 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en) * 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
CN104136437B (zh) 2012-02-27 2016-05-11 百时美施贵宝公司 N-(5s,6s,9r)-4-(2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-1-基)哌啶-1-羧酸5-氨基-6-(2,3-二氟苯基)-6,7,8,9-四氢-5h-环庚三烯并[b]吡啶-9-基酯半硫酸盐
EP2846801B1 (en) * 2012-05-09 2017-04-05 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
TW201718574A (zh) * 2015-08-12 2017-06-01 美國禮來大藥廠 Ｃｇｒｐ受體拮抗劑
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
AU2019242604A1 (en) 2018-03-25 2020-10-22 Pfizer Ireland Pharmaceuticals Rimegepant for CGRP related disorders
CN114805206A (zh) * 2021-01-27 2022-07-29 奥锐特药业(天津)有限公司 高光学纯度瑞美吉泮中间体的工业化制备方法
MX2023010115A (es) 2021-03-02 2023-11-09 Cgrp Diagnostics Gmbh Tratamiento y/o reducción de la aparición de la migraña.
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
CN115850266A (zh) * 2021-09-26 2023-03-28 奥锐特药业(天津)有限公司 瑞美吉泮新晶型及其制备方法
CN116554164A (zh) * 2022-01-27 2023-08-08 奥锐特药业(天津)有限公司 一种瑞美吉泮的制备方法
WO2023175632A1 (en) * 2022-03-17 2023-09-21 Msn Laboratories Private Limited, R&D Center Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof
CN116478211B (zh) * 2022-04-19 2023-10-24 石家庄迪斯凯威医药科技有限公司 一种新型cgrp受体拮抗剂及其用途
CN115060824B (zh) * 2022-06-14 2024-03-12 浙江宏元药业股份有限公司 一种瑞米吉泮中间体对映异构体杂质的液相色谱检测方法
WO2024022434A1 (zh) * 2022-07-29 2024-02-01 熙源安健医药（上海）有限公司 吡啶并环庚烷类衍生物及其制备方法和用途
CN115677694A (zh) * 2022-11-30 2023-02-03 南通常佑药业科技有限公司 一种瑞美吉泮的合成方法
WO2024180562A1 (en) * 2023-03-02 2024-09-06 Natco Pharma Limited A process for the preparation of pure crystalline rimegepant and its salts thereof
CN117486798A (zh) * 2023-12-21 2024-02-02 南京威凯尔生物医药科技有限公司 一种瑞美吉泮中间体盐酸盐的晶型及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2005085228A1 (ja) 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. シクロアルカノピリジン誘導体
US8039460B2 (en) 2004-10-13 2011-10-18 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US20060084708A1 (en) 2004-10-14 2006-04-20 Bayer Materialscience Llc Rigid foams with good insulation properties and a process for the production of such foams
WO2006047196A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. Cgrp receptor antagonists
AU2007238894A1 (en) 2006-04-10 2007-10-25 Merck Sharp & Dohme Corp. Process for the preparation of pyridine heterocycle CGRP antagonist intermediate
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists

Also Published As

Publication number Publication date
PE20121137A1 (es) 2012-08-30
CY2022023I2 (el) 2023-01-05
JP2017125054A (ja) 2017-07-20
TWI465448B (zh) 2014-12-21
CA2777518C (en) 2017-07-04
CO6460732A2 (es) 2012-06-15
KR101755742B1 (ko) 2017-07-07
US20110251223A1 (en) 2011-10-13
SMT201400019B (it) 2014-05-07
CA2777518A1 (en) 2011-04-21
TN2012000139A1 (en) 2013-09-19
BR112012008828A2 (pt) 2020-09-15
AR110069A2 (es) 2019-02-20
PT2488512E (pt) 2014-02-24
KR20180080343A (ko) 2018-07-11
AU2010306954A1 (en) 2012-05-03
FR22C1044I1 (fr) 2022-09-30
JP6109874B2 (ja) 2017-04-05
BR112012008828B1 (pt) 2021-11-23
EA201270561A1 (ru) 2012-12-28
ZA201203452B (en) 2014-10-29
IL219120A (en) 2016-12-29
EP2488512A1 (en) 2012-08-22
RS53149B (en) 2014-06-30
JP2013508281A (ja) 2013-03-07
CN102656159B (zh) 2015-07-01
MX2012004182A (es) 2012-05-29
LTPA2022516I1 (es) 2022-08-25
US20130053570A1 (en) 2013-02-28
CA2968176C (en) 2019-11-26
FR22C1044I2 (fr) 2023-11-17
KR101990755B1 (ko) 2019-06-18
KR101875353B1 (ko) 2018-07-05
DK2488512T3 (en) 2014-02-24
ES2441192T3 (es) 2014-02-03
CY2022023I1 (el) 2023-01-05
HUS2200033I1 (hu) 2022-08-28
TW201118096A (en) 2011-06-01
IL219120A0 (en) 2012-06-28
CN102656159A (zh) 2012-09-05
JP2015163625A (ja) 2015-09-10
NO2022033I1 (no) 2022-07-22
HK1169390A1 (en) 2013-01-25
PL2488512T3 (pl) 2014-04-30
WO2011046997A1 (en) 2011-04-21
HRP20140111T1 (hr) 2014-03-14
KR20120087940A (ko) 2012-08-07
CA2968176A1 (en) 2011-04-21
SI2488512T1 (sl) 2014-02-28
EA020409B1 (ru) 2014-10-30
KR20170081737A (ko) 2017-07-12
JP6258537B2 (ja) 2018-01-10
CL2012000925A1 (es) 2012-08-31
US8314117B2 (en) 2012-11-20
AU2010306954B2 (en) 2016-05-26
EP2488512B1 (en) 2013-11-27
JP5836279B2 (ja) 2015-12-24
NL301187I2 (nl) 2022-08-04
NZ599281A (en) 2013-01-25

Similar Documents

Publication Publication Date Title
AR078638A1 (es) Antagonistas del receptor de cgrp
AR071314A1 (es) Antagonistas de receptor de cgrp
ES2691068T3 (es) Compuestos de indol e indazol como inhibidores de la necrosis celular
AR070950A1 (es) Compuestos derivados de amina, composiciones farmaceuticas de ellos, compuestos inhibidores de produccion de 11-cis-retinol y metodos para tratar enfermedades y trastornos oftalmicos
AR106945A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
AR062050A1 (es) Derivados de amina utiles como agentes anti-cancerigenos
AR087127A1 (es) Compuestos que se unen a fxr (nr1h4) y modulan su actividad
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR073740A1 (es) Compuestos para el tratamiento de la hepatitis c
ES2570127T3 (es) Compuestos y composiciones como inhibidores de la proteína quinasa
PE20071009A1 (es) Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3
AR048343A1 (es) Agentes terapeuticos para el tratamiento de la migrana
AR051755A1 (es) Compuestos biciclicos y triciclicos antagonistas del receptor cgrp
EA201590284A1 (ru) Дигидропиридон р1 в качестве ингибиторов фактора xia
AR107170A1 (es) Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih
AR080746A1 (es) (r)-n-(3-(7-metil-1h-indazol-5-il)1-(4-(1-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida antagonista de receptores cgrp.
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
AR072241A1 (es) Antagonistas de aminoalquilbifenilo n,n-disustituidos de receptores de prostaglandina d2 y composiciones farmaceuticas que los comprenden
AR066153A1 (es) Derivados de piperidina / piperazina
AR084913A1 (es) Derivados de aril-benzocicloalquil-amida
PE20061207A1 (es) Derivados de bifenil-piperidina como antagonistas de receptores muscarinicos
MX349699B (es) Estabilizante de amina estericamente inhibida.
AR066154A1 (es) Derivados de piperidina / piperazina
AR074583A1 (es) 4-azetidinil-1-heteroaril-ciclohexanol antagonistas del ccr2
MX2011009700A (es) Derivado de amida.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee